method
base
effect
shrna
target
differ
region
htnv
genom
rna
viral
replic
effect
rna
interfer
fragment
gene
construct
vector
design
psilenc
psilencerm
respect
antivir
effect
psilencersm
htnv
evalu
htnvinfect
cell
mice
result
htnvinfect
cell
psilenc
psilencerm
target
viral
nucleocapsid
protein
envelop
glycoprotein
respect
reveal
immunofluoresc
assay
transfect
psilenc
psilencerm
markedli
inhibit
viral
antigen
express
doseand
timedepend
manner
transfect
either
plasmid
significantli
decreas
htnvrna
level
day
postinfectin
dpi
progeni
viru
titer
dpi
mice
infect
lethal
dose
htnv
intraperiton
inject
psilenc
psilencerm
consider
increas
surviv
rate
mean
time
death
significantli
reduc
mean
viru
yield
viral
rna
level
allevi
virusinduc
patholog
lesion
lung
brain
kidney
conclus
plasmidbas
shrna
potent
inhibit
htnv
replic
vitro
vivo
result
provid
basi
develop
shrna
therapeut
htnv
infect
human
hantavirus
repres
one
import
emerg
reemerg
viral
group
becom
global
threat
public
health
differ
area
world
hantavirus
lead
two
sever
febril
diseas
worldwid
ie
hemorrhag
fever
renal
syndrom
hfr
eurasia
due
old
world
hantaviru
hantaviru
pulmonari
syndrom
hp
america
due
new
world
hantaviru
approxim
hfr
case
report
year
worldwid
mortal
rate
reach
hantavirus
belong
genu
hantaviru
bunyavirida
famili
envelop
singlestrand
negativesens
triseg
rna
virus
viral
genom
consist
larg
l
medium
small
segment
encod
rnadepend
rna
polymeras
two
envelop
glycoprotein
gn
gc
nucleocapsid
n
protein
variat
segment
may
influenc
antigen
virul
hantavirus
extens
effort
made
search
effect
prevent
treatment
measur
hantaviru
infect
ribavirin
broadspectrum
synthet
nucleosid
analog
report
effect
inhibit
replic
hantaan
viru
htnv
old
world
hantaviru
and
viru
andv
new
world
hantaviru
vitro
vivo
howev
current
prophylact
vaccin
therapeut
antivir
hantaviru
infect
approv
fda
therefor
explor
novel
treatment
strategi
hantaviru
infect
urgent
necessari
rna
interfer
rnai
short
doublestrand
rna
inducedprocess
target
mrna
specif
sequenc
degrad
posttranscript
gene
silenc
mediat
endogen
microrna
mirna
exogen
small
interf
rna
sirna
short
hairpin
rna
shrna
rnai
technolog
recogn
promis
novel
nucleic
acidbas
tool
use
variou
diseas
includ
cancer
infecti
diseas
genet
disord
rnai
reagent
also
report
potent
specif
inhibit
replic
differ
virus
includ
hiv
hbv
hsv
sarcov
influenza
viru
coxsackieviru
other
thu
develop
rnai
possibl
antivir
agent
hantaviru
infect
consider
interest
present
studi
examin
effect
shrna
htnv
replic
use
shrna
target
differ
region
htnv
genom
rna
transfect
two
effect
shrna
shrna
express
vector
name
result
vector
psilenc
psilencerm
antivir
effect
psilencersm
htnv
ultim
evalu
tissu
cultur
mous
model
cell
obtain
china
center
type
cultur
collect
cctcc
maintain
dmem
supplement
fetal
bovin
serum
fb
gibco
carlsbad
ca
usa
lglutamin
uml
penicillin
streptomycin
dmem
contain
fb
use
maintain
medium
viral
infect
stock
hantaan
viru
strain
obtain
institut
virolog
chines
academi
prevent
medicin
beij
china
propag
cell
htnv
titrat
perform
regularli
base
indirect
immunofluoresc
assay
ifa
describ
previous
tcid
determin
ml
shrna
design
select
two
individu
target
site
select
genbank
access
number
gene
genbank
access
number
htnv
design
shrna
sequenc
perform
accord
method
refer
literatur
involv
use
webbas
blockit
rnai
design
program
http
rnaidesign
thermofishercomrnaiexpress
blast
search
http
wwwncbinlmnihgovblast
perform
exclud
possibl
homolog
sequenc
sequenc
posit
shrna
illustr
tabl
design
structur
contain
follow
sequenc
strand
sirna
cttgcttc
loop
region
antisens
strand
sirna
tatagtga
promot
target
gene
present
tabl
neg
control
chosen
target
posit
leishmania
sequenc
dna
templat
synthes
sangon
biotech
shanghai
co
ltd
shrna
gener
use
shrna
product
kit
qiagen
describ
previous
cell
grown
plate
confluenc
transfect
specif
control
shrna
nmoll
rnaifect
transfect
reagent
qiagen
germantown
md
usa
h
transfect
cell
infect
tcid
htnv
per
well
viral
rna
detect
qrtpcr
hour
postinfect
hpi
determin
interfer
effici
viral
titer
determin
hpi
shrna
shrna
found
effect
shrna
term
inhibit
htnv
select
use
subsequ
experi
construct
shrna
vector
target
gene
htnv
synthes
oligonucleotid
contain
shrna
sequenc
bamh
hind
iii
sequenc
termini
design
illustr
tabl
accord
instruct
manufactur
rnai
design
invitrogen
carlsbad
ca
usa
two
oligo
sequenc
npg
complementari
oligonucleotid
anneal
insert
bamh
ihind
iii
site
vector
transform
clone
pcr
enzym
digest
identifi
shrna
express
plasmid
sent
sequenc
analysi
confirm
subsequ
design
psilenc
psilencerm
one
day
transfect
cell
seed
plate
cell
per
well
confluent
cell
transfect
psilenc
psilencerm
psilenc
psilencerblank
vector
lipofectamin
invitrogen
accord
manufactur
instruct
transfect
effici
accord
gfp
express
cotransfect
plasmid
hpi
cell
infect
tcid
ml
day
postinfect
dpi
antigen
slide
prepar
detect
htnv
protein
express
ifa
parallel
experi
cell
individu
well
plasmid
transfect
group
collect
dpi
viral
rna
detect
dpi
cultur
subject
two
cycl
freez
thaw
follow
centrifug
low
speed
supernat
serial
dilut
inocul
cell
final
titrat
ifa
studi
approv
ethic
committe
wuhan
univers
school
medicin
work
infect
mice
perform
anim
biosafeti
level
laboratori
anim
research
center
wuhan
univers
human
conduct
complianc
chines
anim
protect
act
nation
research
council
criteria
specif
pathogenfre
pregnant
balbc
mice
obtain
anim
research
center
wuhan
univers
suckl
mice
old
intracrani
inocul
htnv
viral
stock
ld
mice
randomli
divid
group
mice
per
group
intraperiton
inject
plasmid
psilenc
psilencerm
psilenc
vector
concentr
pb
normal
control
viral
control
dpi
respect
treatment
perform
surviv
rate
studi
mice
observ
daili
follow
infect
mortal
rate
mean
time
death
mtd
estim
four
mice
group
sacrif
dpi
brain
tissu
collect
viral
rna
detect
qrtpcr
dpi
brain
lung
kidney
dissect
sacrif
anim
use
patholog
examin
h
e
stain
experiment
point
dpi
brain
lung
kidney
harvest
weigh
homogen
weightvolum
suspens
test
medium
homogen
frozen
thaw
twice
centrifug
round
per
minut
min
viru
titer
determin
describ
experiment
point
dpi
blood
sampl
collect
pool
group
detect
sera
quantikin
quantit
sandwich
enzym
immunoassay
accord
manufactur
instruct
qrtpcr
analysi
total
rna
extract
cell
tissu
use
trizol
reagent
invitrogen
usa
follow
manufactur
instruct
firststrand
cdna
synthes
revers
transcript
ng
total
rna
use
random
primer
promega
mmlv
revers
transcriptas
promega
min
min
min
min
amplif
perform
use
follow
primer
set
htnv
forward
htnv
revers
human
gapdh
forward
human
gapdh
revers
mous
gapdh
forward
mous
gapdh
revers
plasmid
pgemthtnv
pgemthuman
gapdh
pgemtmous
gapdh
store
laboratori
use
gener
standard
curv
absolut
quantif
htnv
viral
gene
perform
previous
describ
data
present
vrna
copiesng
gapdh
mrna
immunofluoresc
assay
ifa
ifa
perform
detect
hantaviru
antigen
infect
cell
previous
report
monoclon
antibodi
target
nucleocapsid
protein
dilut
provid
institut
virolog
chines
academi
prevent
medicin
beij
china
rabbit
polyclon
antibodi
target
glycoprotein
dilut
provid
prof
john
w
huggin
virolog
divis
unit
state
armi
medic
research
institut
infecti
diseas
incub
fitcconjug
goat
antimous
antirabbit
igg
sigma
aldrich
dilut
secondari
antibodi
use
cell
cytoplasm
stain
red
evan
blue
imag
collect
use
fluoresc
microscop
nikon
data
analyz
spss
softwar
data
express
experi
oneway
anova
use
assess
signific
differ
mean
p
valu
consid
statist
signific
inhibit
htnv
product
cell
shrna
shrna
design
specif
target
gene
htnv
efficaci
shrna
inhibit
htnv
replic
evalu
transfect
cell
nmoll
shrna
folliu
yy
et
al
acta
pharmacologica
sinica
npg
low
infect
cell
tcid
ml
illustr
figur
transfect
shrna
result
inhibit
viral
rna
transcript
hpi
p
vs
viru
group
cell
treat
shrna
hpi
effici
viral
gene
inhibit
p
vs
viru
group
protect
effect
observ
cell
treat
shcrk
yieldreduct
assay
cultur
sampl
collect
hpi
titer
determin
inhibitori
effect
four
shrna
htnv
replic
evalu
four
shrna
reduc
htnv
yield
approxim
log
log
compar
control
figur
base
result
viral
antigen
express
result
detect
ifa
data
shown
conclud
shrna
target
segment
htnv
gene
abl
inhibit
rna
transcript
viru
product
htnvinfect
cell
exhibit
stronger
inhibitori
effect
htnv
thu
select
insert
rnai
vector
result
vector
design
psilenc
psilencerm
rnai
psilenc
psilencerm
plasmid
construct
antivir
effect
evalu
detect
viral
protein
synthesi
rna
transcript
progeni
viru
titer
htnvinfect
cell
transfect
effici
evalu
accord
gfp
express
cotransfect
plasmid
reach
approxim
treatment
psilenc
psilencerm
concentr
significantli
decreas
viral
antigen
express
htnvinfect
cell
dpi
figur
percentag
posit
cell
declin
increas
dose
transfect
rnai
plasmid
figur
cell
posit
nucleocapsid
protein
stain
psilenc
treatment
group
compar
psilencerblank
treatment
group
figur
similarli
correspond
glycoprotein
posit
stain
rate
psilencerm
treatment
group
figur
result
indic
plasmid
transfect
achiev
effect
inhibit
viral
protein
synthesi
detect
reduct
viral
antigen
express
htnvinfect
cell
treat
plasmid
throughout
cours
infect
greatest
inhibitori
rate
note
dpi
psilenc
psilencerm
figur
moreov
antivir
effect
last
least
psilenc
psilencerm
dpi
efficaci
inhibit
htnv
replic
psilenc
psilencerm
also
evalu
detect
viral
rna
transcript
hpi
follow
plasmid
treatment
illustr
figur
cell
treat
rnai
plasmid
effici
gene
inhibit
reach
hpi
respect
hpi
cultur
sampl
harvest
serial
dilut
assay
determin
viral
titer
illustr
figur
two
shrna
express
plasmid
reduc
htnv
yield
approxim
log
compar
control
figur
taken
togeth
result
indic
psilenc
psilencerm
significantli
reduc
viral
rna
transcript
viral
antigen
synthesi
progeni
viru
product
htnv
infect
cell
suckl
mice
infect
htnv
describ
treat
psilenc
psilencerm
dpi
respect
compar
psilencerblank
group
psilencersand
psilencermtr
anim
die
later
exhibit
reduc
clinic
sign
includ
weight
loss
ruffl
fur
huddl
tendenc
paralysi
hind
leg
spasm
placebotr
psilencerblanktr
mice
die
mtd
wherea
treatment
rnai
plasmid
increas
surviv
rate
mtd
figur
rnai
plasmid
treatment
increas
surviv
rate
mtd
p
rnai
plasmid
therapi
result
signific
reduct
viral
titer
brain
lung
kidney
sampl
collect
dpi
figur
homogen
serial
dilut
assay
determin
viral
titer
ifa
infecti
viral
particl
detect
lung
kidney
brain
survivor
dpi
dynam
viral
load
brain
analyz
qrtpcr
indic
psilenc
psilencerm
significantli
decreas
htnv
gene
express
dpi
figur
four
anim
group
sacrif
dpi
brain
lung
kidney
collect
patholog
examin
illustr
figur
viral
control
group
lung
section
display
thicken
alveolar
wall
interstiti
lymphocyt
macrophag
infiltr
hemorrhag
brain
tissu
exhibit
scatter
hemorrhag
congest
edema
focal
necrosi
kidney
exhibit
focal
renal
interstiti
hemorrhag
congest
psilenc
psilencerm
treatment
decreas
sever
viral
lesion
brain
lung
kidney
tissu
htnv
infect
emerg
one
severest
infecti
diseas
threaten
global
health
signific
worldwid
econom
influenc
present
studi
demonstr
vectorbas
shrna
target
specif
sequenc
segment
htnv
inhibit
express
replic
htnv
vitro
vivo
result
provid
new
therapeut
candid
treatment
htnv
infect
sinc
discoveri
rnai
synthet
sirna
duplex
gener
consist
nucleotid
overhang
use
target
viral
rna
sequencespecif
manner
follow
transfect
howev
applic
sirna
limit
short
halfliv
high
cost
synthet
sirna
instabl
due
degrad
nucleas
anoth
method
induc
rnai
via
transfect
plasmid
express
antivir
shorthairpin
rna
shrna
method
also
effici
mean
elicit
rnai
vivo
result
indic
except
ribavirin
antivir
drug
treatment
hantaviru
infect
identifi
sever
member
bunyavirida
famili
particularli
htnv
sensit
ribavirin
report
ribavirin
induc
decreas
vrna
level
htnv
infect
dpi
equival
vitro
effect
psilenc
observ
experi
regard
vivo
administr
rnai
plasmid
treatment
increas
surviv
rate
lethal
htnvinfect
suckl
mous
model
zhou
et
al
report
npspecif
sirna
express
plasmid
pbabenp
protect
two
eight
mice
challeng
lethal
dose
avian
influenza
viru
kill
control
mice
result
similar
antivir
effect
sirna
express
plasmid
htnv
observ
vivo
experi
howev
notic
ribavirin
report
capabl
afford
protect
lethal
and
viru
infect
hamster
also
increas
surviv
rate
seovinfect
suckl
icr
mice
explan
phenomena
may
relat
deliveri
sirna
shrna
express
plasmid
distribut
brain
bloodbrain
barrier
bbb
newborn
mice
immatur
howev
nonvir
vector
psilenc
shrna
express
vector
readili
cross
cellular
membran
stabli
introduc
cell
studi
requir
solv
problem
frequent
consid
hurdl
develop
sirnabas
therapeut
knowledg
first
report
inhibit
hantaviru
infect
shrna
thu
report
enrich
antivir
spectrum
rnai
therapi
recent
year
known
emerg
virus
pose
increasingli
seriou
threat
public
health
effect
vaccin
antivir
drug
avail
major
virus
transfect
shrnaencod
plasmid
probabl
bestsuit
treatment
acut
viral
infect
particularli
among
peopl
infect
viru
strain
resist
convent
antivir
case
sever
reemerg
diseas
howev
number
barrier
medic
applic
remain
solv
eg
improv
deliveri
strategi
safeti
stabil
sirna
issu
